Compare AbCellera Biologics Inc (ABCL) vs Advanced Micro Devices (AMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Advanced Micro Devices — how do they compare? AbCellera Biologics Inc trades at $9.31 (market cap $2.85B), while Advanced Micro Devices trades at $474.87 (market cap $766.54B). The key difference: Advanced Micro Devices is far larger — about 269× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Advanced Micro Devices nearer its low. Which is the better fit depends on your goals.
| ABCL | AMD | |
|---|---|---|
Market Cap | $2.85B | $766.54B |
Sector | Health | Technology |
52-Week High | $9.34 | $580.91 |
52-Week Low | $2.78 | $151.14 |
Enterprise Value | $2.45B | $757.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
AMD trades at $474.32, down 1.87% on the day, with a bearish technical signal but strong fundamental momentum. The stock shows elevated valuation metrics (P/E 119.79, P/S 18.75) despite impressive revenue growth to $34.64B in 2025 and consistent earnings beats. Analyst consensus remains strongly bullish with a $615.11 price target, while recent news highlights AMD's positioning in the competitive AI semiconductor market.
AMD presents a growth story driven by AI and data center demand, with projected revenue reaching $41.3B in 2026. However, high valuations and intense competition from NVIDIA represent significant risks. The stock offers substantial upside to analyst targets but requires careful monitoring of execution and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →
